Abstract
Engineered cell therapy–focused Sana Biotechnology has completed its initial funding round, bringing in a whopping $700 million. The funds will be used to develop preclinical drug candidates, estab...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have